Seeking Alpha

Navidea Biopharmaceuticals (NAVB -4.3%) slips on disappointment that the FDA is giving a six...

Navidea Biopharmaceuticals (NAVB -4.3%) slips on disappointment that the FDA is giving a six month window to approve Lymphoseek, its Lymphoma diagnostic tool, rather than the two-month review time-frame some investors were betting on. The agency had rejected NAVB's first application in September, citing problems caused by its third-party manufacturer, and it now has to re-inspect the manufacturing site before deciding on the drug.
Comments (2)
  • pjg69ny
    , contributor
    Comments (136) | Send Message
     
    How is this not good news we knew it would be a Class 2 resubmission as the FDA must reinspect the facility. This stock always sells off in a knee jerk reaction.
    14 Nov 2012, 11:20 AM Reply Like
  • skewb
    , contributor
    Comments (8) | Send Message
     
    exactly
    14 Nov 2012, 01:05 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|